Omarigliptin regulatory update

Japan approved once-weekly, oral Marizev omarigliptin from Merck to treat Type II diabetes. The company plans to submit an NDA by year end to FDA for the dipeptidyl peptidase-4 ( DPP-4; CD26) inhibi...